SOPHiA GENETICS (NASDAQ:SOPH) CEO Sells $87,365.00 in Stock

Key Points

• CEO Jurgi Camblong sold 17,473 shares on April 15 for $87,365 under a pre-arranged Rule 10b5-1 plan to cover tax withholding; across mid-March to mid-April he sold ~91,569 shares for roughly $449K, leaving him with 3,646,967 shares (a 0.48% ownership decrease worth about $18.23M).
• SOPHiA GENETICS shares traded at $5.12 (up ~1%) with a market cap of ~$350.7M; the company missed EPS estimates on March 3 (‑$0.28 vs. ‑$0.20) but slightly beat revenue at $21.71M, and analysts remain mixed (consensus rating: Hold, target $7.50).

SOPHiA GENETICS SA (NASDAQ:SOPH - Get Free Report) CEO Jurgi Camblong sold 17,473 shares of the company's stock in a transaction on Wednesday, April 15th. The shares were sold at an average price of $5.00, for a total transaction of $87,365.00. Following the completion of the sale, the chief executive officer directly owned 3,646,967 shares in the company, valued at approximately $18,234,835. This represents a 0.48% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Jurgi Camblong also recently made the following trade(s):

• On Tuesday, April 14th, Jurgi Camblong sold 43,129 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.96, for a total transaction of $213,919.84.
• On Monday, April 13th, Jurgi Camblong sold 4,399 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.76, for a total transaction of $20,939.24.
• On Friday, April 10th, Jurgi Camblong sold 12,232 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.72, for a total transaction of $57,735.04.
• On Thursday, April 9th, Jurgi Camblong sold 1,950 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.74, for a total transaction of $9,243.00.
• On Wednesday, April 8th, Jurgi Camblong sold 2,800 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.84, for a total transaction of $13,552.00.
• On Tuesday, April 7th, Jurgi Camblong sold 2,500 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.86, for a total transaction of $12,150.00.
• On Monday, April 6th, Jurgi Camblong sold 2,600 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.85, for a total transaction of $12,610.00.
• On Thursday, March 19th, Jurgi Camblong sold 4,486 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.77, for a total transaction of $21,398.22.

SOPHiA GENETICS Stock Up 1.0%

NASDAQ SOPH traded up $0.05 on Thursday, hitting $5.12. 125,040 shares of the company were exchanged, compared to its average volume of 181,146. The company has a market cap of $350.67 million, a PE ratio of -10.04 and a beta of 1.04. SOPHiA GENETICS SA has a 12 month low of $2.58 and a 12 month high of $5.70. The stock has a fifty day moving average of $4.74 and a 200-day moving average of $4.72. The company has a current ratio of 1.96, a quick ratio of 1.84 and a debt-to-equity ratio of 1.01.

SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last issued its earnings results on Tuesday, March 3rd. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.08). SOPHiA GENETICS had a negative return on equity of 50.60% and a negative net margin of 44.22%.The company had revenue of $21.71 million for the quarter, compared to the consensus estimate of $21.20 million. As a group, analysts forecast that SOPHiA GENETICS SA will post -0.96 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on SOPH shares. Weiss Ratings restated a "sell (d-)" rating on shares of SOPHiA GENETICS in a report on Thursday, January 22nd. BTIG Research upped their target price on shares of SOPHiA GENETICS from $7.00 to $8.00 and gave the stock a "buy" rating in a report on Wednesday. Finally, Guggenheim upped their target price on shares of SOPHiA GENETICS from $6.00 to $7.00 and gave the stock a "buy" rating in a report on Monday, January 26th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of "Hold" and a consensus price target of $7.50.

Institutional Trading of SOPHiA GENETICS

Institutional investors and hedge funds have recently made changes to their positions in the company. Savvy Advisors Inc. purchased a new stake in shares of SOPHiA GENETICS in the third quarter valued at about $48,000. Squarepoint Ops LLC purchased a new stake in shares of SOPHiA GENETICS in the third quarter valued at about $49,000. Perkins Capital Management Inc. purchased a new stake in shares of SOPHiA GENETICS in the fourth quarter valued at about $49,000. Quadrature Capital Ltd purchased a new stake in shares of SOPHiA GENETICS in the fourth quarter valued at about $54,000. Finally, XTX Topco Ltd purchased a new stake in shares of SOPHiA GENETICS in the fourth quarter valued at about $55,000. Hedge funds and other institutional investors own 31.59% of the company's stock.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.